Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE versus COLESTIPOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE versus COLESTIPOL HYDROCHLORIDE.
CHOLESTYRAMINE vs COLESTIPOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant